Pfizer Inc. $PFE Stock: Pzena Investment Management LLC Boosts Stake

Pzena Investment Management LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 1.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,050,227 shares of the biopharmaceutical company’s stock after purchasing an additional 91,305 shares during the quarter. Pzena Investment Management LLC owned 0.11% of Pfizer worth $172,552,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Retirement Wealth Solutions LLC lifted its position in Pfizer by 144.6% during the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 509 shares during the last quarter. Keb Asset Management LLC purchased a new position in shares of Pfizer in the 2nd quarter worth $26,000. Field & Main Bank purchased a new position in shares of Pfizer in the 2nd quarter worth $27,000. Bullseye Investment Management LLC bought a new stake in shares of Pfizer in the 2nd quarter worth about $28,000. Finally, Timbuktu Capital Management LLC bought a new stake in shares of Pfizer in the 2nd quarter worth about $29,000. Institutional investors own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat third-quarter estimates, reporting adjusted EPS of $0.87 and revenue of $16.58 billion. It raised its 2026 revenue outlook to $62–$64 billion and adjusted EPS forecast to $2.95–$3.05, citing execution and cost savings. Reuters article
• Positive Sentiment: Growth in newer and acquired medicines is helping offset pandemic-product declines: these products grew 32% operationally in Q3, while non-COVID products overall grew 7%. This supports Pfizer’s effort to build growth beyond COVID sales. The Motley Fool article
• Positive Sentiment: Scotiabank raised its price target to $35 and maintained a “sector outperform” rating, signaling further potential upside. Ticker Report article
• Neutral Sentiment: Pfizer named Cecile Guegan permanent CFO after she served in the interim role. The appointment provides leadership continuity, though its near-term financial impact is unclear. Business Wire announcement
• Negative Sentiment: COVID-related product sales continued to decline, and revenue was slightly lower year over year. UBS and Citi raised their targets to $30 and RBC to $28, but each retained a neutral or sector-perform rating—targets below the recent share price that may temper expectations. UBS rating

Pfizer Stock Up 2.6%

NYSE:PFE opened at $30.79 on Thursday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The firm has a market cap of $175.52 billion, a PE ratio of 43.99, a price-to-earnings-growth ratio of 2.04 and a beta of 0.31. The company has a 50-day moving average of $28.69 and a 200 day moving average of $26.86. Pfizer Inc. has a 1-year low of $23.62 and a 1-year high of $31.06.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.98%. The firm had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter in the prior year, the company earned $0.87 EPS. The company’s revenue was down .4% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 5.6%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. Royal Bank Of Canada upped their target price on shares of Pfizer from $25.00 to $28.00 and gave the company a “sector perform” rating in a research report on Wednesday. JPMorgan Chase & Co. lifted their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. Scotiabank upped their price objective on Pfizer from $33.00 to $35.00 and gave the company a “sector outperform” rating in a research report on Wednesday. Argus set a $40.00 target price on Pfizer in a research report on Wednesday. Finally, Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Five analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $29.81.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.